Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Surge

What Jazz Pharmaceuticals’ Recent Performance Tells Investors

Jazz Pharmaceuticals (JAZZ) has drawn fresh investor attention after a strong run in its stock, with the share price rising about 19% over the past month and 37% over the past 3 months.

See our latest analysis for Jazz Pharmaceuticals.

At a latest share price of $226.96, Jazz Pharmaceuticals has posted an 11.8% 7 day share price return and an 18.9% 30 day share price return, while the 1 year total shareholder return of 130.6% suggests strong momentum has already been in place for some time.

If Jazz’s recent move has you thinking more broadly about high growth themes in healthcare, it could be worth sizing up a curated list of 35 healthcare AI stocks

With the stock already up sharply and trading not far from analyst targets, the key question now is whether Jazz still trades at a discount to its underlying potential or if the market is already pricing in future growth.

Most Popular Narrative: 1% Overvalued

At a last close of $226.96 against a narrative fair value estimate of about $225.53, Jazz is framed as slightly ahead of that valuation, with the story hinging on how its pipeline and margins evolve from here.

Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands, positioning Jazz for steady long-term market share and revenue growth.

Read the complete narrative.

Curious what sits behind that growth path, margin uplift and the earnings step change implied here? The narrative leans on a specific revenue glide path, a higher profitability profile and a future earnings multiple that is different from today. The full set of assumptions connects these moving parts into the fair value.

Result: Fair Value of $225.53 (ABOUT RIGHT)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still clear pressure points, including potential generic competition for key sleep drugs and execution risk around oncology trial timelines and launches that could unsettle this narrative.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Another Way To Look At Jazz’s Valuation

The narrative fair value of $225.53 suggests Jazz is roughly in line with analyst expectations, yet our DCF model points to a very different picture, with an estimated future cash flow value of $808.36 and the stock trading about 72% below that. Which story do you think is closer to reality?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With mixed signals across valuation models and sentiment, this is a good moment to look through the numbers yourself and decide what truly matters for your portfolio, starting with 3 key rewards and 4 important warning signs.

Ready To Hunt For Your Next Idea?

If Jazz is already on your radar, do not stop there. Broaden your opportunity set now or you risk missing stocks that may fit you even better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com